# US 2013/0261045 A1 · Green tea polyphenol alpha secretase enhancers and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0261045 A1
- Document ID: US20130261045A1
- Status: Published application
- Kind: A1
- Application number: 13/708,219
- Filed: 2012-12-07
- Published: 2013-10-03
- Earliest claimed: 2005-04-26
- Assignees: University of South Florida
- Applicants: University of South Florida
- Inventors: ROLAND DOUGLAS SHYTLE; JUN TAN
- Web page: https://patentgrep.com/patent/US20130261045A1

## CPC

- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12Q 1/37: involving peptidase or proteinase
- G01N 33/5058: {Neurological cells}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The subject invention concerns materials and methods for treating or preventing a neurodegenerative condition or disease associated with β-amyloid peptide deposition in neural tissue in a person or animal by administering a therapeutically effective amount of a polyphenol, or an analog, isomer, metabolite, or prodrug thereof, that increases expression or activity of a protein that exhibits α-secretase activity. The subject invention also provides methods to increase α-secretase expression and/or activity in cells by administering polyphenol flavonoids like (−)-epigallocatechin-3-gallate (EGCG) and epicatechin (EC), two polyphenols derived from green tea and other plants and that can be produced synthetically. Furthermore, there are provided methods to decrease or inhibit the production of Aβ1-40 or Aβ1-42 by administering the EGCG and EC compounds, their analogs, metabolites, and prodrugs.

## Claims

### Claim 1

A method for:
i) treating or preventing a neurodegenerative disease or condition associated with β-amyloid peptide deposition in neural tissue, said method comprising administering to a person or animal in need thereof an effective amount of a polyphenol, or an analog, isomer, metabolite, or prodrug thereof, that increases expression or activity of a protein having α-secretase enzymatic activity; or
ii) decreasing or inhibiting deposition of β-amyloid peptide in neural tissue, said method comprising contacting said neural tissue with an effective amount of a polyphenol, or an analog, isomer, metabolite, or prodrug thereof, that increases expression or activity of a protein having α-secretase enzymatic activity; or
iii) decreasing levels of a β-amyloid peptide produced by a cell, said method comprising contacting a cell with an effective amount of a polyphenol, or an analog, isomer, metabolite, or prodrug thereof, that increases expression or activity of a protein having α-secretase enzymatic activity.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said polyphenol is epigallocatechin-3-gallate (EGCG) or epicatechin (EC).

### Claim 3 (depends on 1)

The method according to claim 1, wherein said neurodegenerative disease or condition is Alzheimer's disease.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said neural tissue is central nervous system tissue.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said neural tissue is brain tissue.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said polyphenol is purified to a level that compounds that antagonize expression or activity of said protein are not present in detectable amounts.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said compounds that antagonize α-secretase activity are gallocatechin and (−)catechin.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said polyphenol is provided in a pharmaceutically acceptable composition.

### Claim 9 (depends on 8)

The method according to claim 8, wherein said pharmaceutically acceptable composition comprises pharmaceutically acceptable salts of said polyphenol.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said polyphenol is administered orally, rectally, nasally, topically, vaginally, parenterally, or by pulmonary administration, or by intra-arterial, intramuscular, intravenous, or intraperitoneal injection.

### Claim 11 (depends on 8)

The method according to claim 8, wherein said pharmaceutical composition is formulated as an ointment, cream, suspension, lotion, powder, solution, paste, gel, spray, aerosol, or oil.

### Claim 12 (depends on 1)

The method according to claim 1, wherein said polyphenol is provided in a purified form.

### Claim 13 (depends on 1)

The method according to claim 1, wherein said polyphenol is administered simultaneously or sequentially with a compound or agent selected from the group consisting of galantamine, deprenyl, cdp choline, folate, Vitamin B12, Vitamin B6, piracetam, vinpocetine, idebenone, pyritinol, memantine, anti-oxidants, free radical scavenging agents, peptides, growth factors, antibiotics, bacteriostatic agents, immunosupressives, anti-coagulants, buffering agents, anti-inflammatory agents, anti-pyretics, time released binders, anesthetics, steroids, corticosteroids, or a combination of any of the forgoing.

### Claim 14 (depends on 1)

The method according to claim 1, wherein said method further comprises administering compounds or agents that inhibit or decrease expression or activity of a protein having β-secretase activity or γ-secretase activity.

### Claim 15

The method according to claim, 1 wherein the method further comprises identifying a person or animal afflicted with or at risk of developing said neurodegenerative disease or condition.

### Claim 16 (depends on 1)

The method according to claim 1, wherein said α-secretase enzyme is ADAM10.

### Claim 17 (depends on 1)

The method according to claim 1, wherein said cell is a neural cell.

### Claim 18

A method for:
i) inducing or promoting a neurodegenerative disease or condition associated with β-amyloid deposition in an animal, said method comprising administering to an animal an effective amount of an agent or compound that inhibits expression or activity of a protein having α-secretase enzymatic activity; or
ii) for screening for candidate drugs or compounds that can be used to treat or prevent a neurodegenerative disease or condition in a person or animal, said method comprising assaying said drug or compound to determine if said drug or compound increases expression or activity of an α-secretase enzyme; or
iii) for increasing production of α-CTF and/or s-APP-α by a cell, said method comprising contacting said cell with an effective amount of a polyphenol, or an analog, isomer, metabolite, or prodrug thereof, that increases expression or activity of a protein having α-secretase enzymatic activity.

### Claim 19

A composition comprising a polyphenol, or an analog, isomer, metabolite, or prodrug thereof, that increases expression or activity of a protein having α-secretase enzymatic activity, and, optionally, an agent or compound that inhibits or decreases expression or levels of protein having β-secretase enzymatic activity or γ-secretase enzymatic activity, and, optionally, a pharmaceutically acceptable carrier or diluent.

### Claim 20 (depends on 19)

The composition according to claim 19, wherein said polyphenol is provided in purified form.

### Claim 21 (depends on 20)

The composition according to claim 20, wherein said polyphenol is purified to a level wherein compounds that antagonize the activity of the polyphenols are removed or decreased to a level wherein they do not antagonize the action of said polyphenol.
